Fulltext

Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma

Cheong EV 1 , Ho GF 1

Affiliations 

  • 1 Department of Clinical Oncology Menara Timur University of Malaya Medical Centre Kuala Lumpur Malaysia
Clin Case Rep, 2021 Apr;9(4):2264-2268.
PMID: 33936677 DOI: 10.1002/ccr3.4009

Abstract

The development of resistance to trastuzumab in HER2-positive gastroesophageal cancer remains a problem. The use of dual HER2 blockade to overcome this is a therapeutic strategy that should be researched more extensively.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications